Top

Published in:

21-07-2023 | Lung Cancer | RESEARCH ARTICLE

Relationship between hemoglobin and lung cancer: evidence from Mendelian randomization and National Health and Nutrition Examination Survey

Authors: Peixin Dong, Wenjie Li, Jiating Deng, Lixia Huang, Baomo Liu, Shuaishuai Wang, Xiongye Xu, Yan Su, Ziying Lin, Shaoli Li, Jincui Gu, Yanli Qiu, Yanbin Zhou

Published in: Clinical and Translational Oncology | Issue 3/2024

Abstract

Background

Lung cancer is the primary cause of cancer-related mortality worldwide. Hemoglobin (Hb) represents the most widely utilized test parameter in clinical settings. However, few articles have examined the causal relationship between Hb concentration and lung cancer incidence.

Methods

Mendelian randomization (MR) was first conducted to investigate the potential causality between Hb and lung cancer. Sensitivity analyses were applied to validate the reliability of MR results. Then, the National Health and Nutrition Examination Survey (NHANES) database was used to verify the effect of Hb on the prognosis of lung cancer.

Results

The MR analysis demonstrated that Hb was casually associated with the decreased risk of lung cancer in the European population (OR_IVW 0.84, 95% CI 0.75–0.95, p = 0.006; OR_{Weighted-median} 0.78, 95% CI 0.65–0.94, p = 0.008; OR_MR-Egger 0.82, 95% CI 0.64–1.04, p = 0.11). The results from the NHANES database showed that a high value of Hb was associated with better outcomes for patients with lung cancer (HR 0.45, 95% CI 0.26–0.79, p = 1.6E−03).

Conclusions

Our study provides further evidence for the relationship between Hb levels and lung cancer, highlighting the potential significance of Hb as a biomarker for predicting the risk and prognosis of lung cancer.

Available only for authorised users

Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ Jr, Wu YL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311. https://doi.org/10.1016/S0140-6736(16)30958-8.CrossRefPubMed

Chen C, Song Z, Wang W, Zhou J. Baseline anemia and anemia grade are independent prognostic factors for stage IV non-small cell lung cancer. Mol Clin Oncol. 2021;14(3):59. https://doi.org/10.3892/mco.2021.2221.CrossRefPubMedPubMedCentral

Qu X, Zhang T, Ma H, Sui P, Du J. Lower mean corpuscular hemoglobin concentration is associated with unfavorable prognosis of resected lung cancer. Future Oncol. 2014;10(14):2149–59. https://doi.org/10.2217/fon.14.121.CrossRefPubMed

Manegold C. The causes and prognostic significance of low hemoglobin levels in tumor patients. Strahlenther Onkol. 1998;174(Suppl 4):17–9.PubMed

Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synth Methods. 2019;10(4):486–96. https://doi.org/10.1002/jrsm.1346.CrossRefPubMedPubMedCentral

Birney E. Mendelian randomization. Cold Spring Harb Perspect Med. 2022;12(4):a041302. https://doi.org/10.1101/cshperspect.a041302.CrossRefPubMed

Vaucher J, Keating BJ, Lasserre AM, Gan W, Lyall DM, Ward J, et al. Cannabis use and risk of schizophrenia: a Mendelian randomization study. Mol Psychiatry. 2018;23(5):1287–92. https://doi.org/10.1038/mp.2016.252.CrossRefPubMed

Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P, et al. Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet. 2014;46(7):736–41. https://doi.org/10.1038/ng.3002.CrossRefPubMedPubMedCentral

Zhang YH, Lu Y, Lu H, Zhang MW, Zhou YM, Li XL, et al. Pre-treatment hemoglobin levels are an independent prognostic factor in patients with non-small cell lung cancer. Mol Clin Oncol. 2018;9(1):44–9. https://doi.org/10.3892/mco.2018.1628.CrossRefPubMedPubMedCentral

10.

García Prim JM, González Barcala FJ, Moldes Rodríguez M, Alvarez Dobañob JM, Hervada Vidal X, Pose Reino A, et al. Impact of hemoglobin level on lung cancer survival. Med Clin (Barc). 2008;131(16):601–4. https://doi.org/10.1157/13127916.CrossRefPubMed

11.

Qureshi N, Orimoloye H, Hansen J, Saechao C, Olsen J, Federman N, et al. Maternal anemia and childhood cancer: a population-based case-control study in Denmark. Cancer Epidemiol. 2023;82:102308. https://doi.org/10.1016/j.canep.2022.102308.CrossRefPubMed

12.

Orimoloye HT, Qureshi N, Lee PC, Wu CK, Saechao C, Federman N, et al. Maternal anemia and the risk of childhood cancer: a population-based cohort study in Taiwan. Pediatr Blood Cancer. 2023;70(3):e30188. https://doi.org/10.1002/pbc.30188.CrossRefPubMed

13.

Bade BC, Dela Cruz CS. Lung cancer 2020: epidemiology, etiology, and prevention. Clin Chest Med. 2020;41(1):1–24. https://doi.org/10.1016/j.ccm.2019.10.001.CrossRefPubMed

14.

Ciaccio C, Coletta A, Coletta M. Role of hemoglobin structural-functional relationships in oxygen transport. Mol Aspects Med. 2022;84:101022. https://doi.org/10.1016/j.mam.2021.101022.CrossRefPubMed

15.

Lee P, Chandel NS, Simon MC. Cellular adaptation to hypoxia through hypoxia inducible factors and beyond. Nat Rev Mol Cell Biol. 2020;21(5):268–83. https://doi.org/10.1038/s41580-020-0227-y.CrossRefPubMedPubMedCentral

16.

Chouaib S, Noman MZ, Kosmatopoulos K, Curran MA. Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene. 2017;36(4):439–45. https://doi.org/10.1038/onc.2016.225.CrossRefPubMed

17.

Qu J, Guo X, Li W, Hou W, Zhang H, Luo L, et al. Preparation of artificial red cell and its application on alleviation of tumor hypoxia. Colloids Surf B Biointerfaces. 2017;160:446–54. https://doi.org/10.1016/j.colsurfb.2017.09.039.CrossRefPubMed

Title: Relationship between hemoglobin and lung cancer: evidence from Mendelian randomization and National Health and Nutrition Examination Survey
Authors: Peixin Dong
Wenjie Li
Jiating Deng
Lixia Huang
Baomo Liu
Shuaishuai Wang
Xiongye Xu
Yan Su
Ziying Lin
Shaoli Li
Jincui Gu
Yanli Qiu
Yanbin Zhou
Publication date: 21-07-2023
Publisher: Springer International Publishing
Keywords: Lung Cancer
Lung Cancer
Lung Cancer
Nutrition
Published in: Clinical and Translational Oncology / Issue 3/2024
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-023-03281-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2024

LncRNA XXYLT1-AS2 promotes tumor progression via autophagy inhibition through ubiquitinated degradation of TFEB in hepatocellular carcinoma

MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis

Difficulties on the access to innovative targeted therapies for lung cancer in Spain

Pattern of practice of re-irradiation for ipsilateral breast tumor recurrence in Italy: a survey by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)

The impact of boost radiation therapy after hysterectomy on cervical cancer patients with close or positive resection margins

The relationship between brain metastasis and HER2 expression status in gastric cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer